Our Work
Latham Advises on Portal Biotech’s US$35 Million Series A
July 3, 2025
London team represents investors on funding round of pioneering biotechnology company.
Latham & Watkins has advised the NATO Innovation Fund, Earlybird Ventures, and We Venture Capital, on the US$35 million Series A funding round of Portal Biotech, a pioneering biotechnology company headquartered in London.
The round was co-led by the NATO Innovation Fund and Earlybird Venture Capital, with substantial participation from existing investors SCVC, Pillar VC, 8VC, Amino Collective, and Outsized, as well as new investors We Venture Capital, British Business Bank, and WS Investment Company (Wilson Sonsini’s venture arm).
The Latham team was led by London corporate partner Shing Lo, with London associate Toni Adejuyigbe.